Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
STOK
STOK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
STOK News
Stoke Therapeutics Launches ADOA Treatment Study with STK-002
5d ago
Newsfilter
Analysis of Stoke Therapeutics Options Trading
Jan 30 2026
NASDAQ.COM
Stoke Therapeutics Secures New Headquarters in Waltham
Jan 27 2026
PRnewswire
Stoke Therapeutics Secures New Headquarters in Waltham for Growth and Research Expansion
Jan 27 2026
Newsfilter
Exelixis Reports Preliminary 2025 Revenue of $2.123 Billion, Shares Drop 4.6%
Jan 12 2026
Benzinga
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
Jan 12 2026
Benzinga
Stoke Therapeutics Accelerates EMPEROR Study Timeline, Expects Patient Enrollment by Q2 2026
Jan 12 2026
NASDAQ.COM
Stoke Accelerates Dravet Syndrome Drug Development, Expects 150 Patient Enrollment by 2026
Jan 11 2026
Businesswire
Stoke Therapeutics Accelerates Zorevunersen Development for Dravet Syndrome, Expects 150 Patient Enrollment by Q2 2026
Jan 11 2026
Yahoo Finance
Stoke Therapeutics CEO Ian F. Smith to Present at J.P. Morgan Healthcare Conference on January 13, 2026
Jan 06 2026
Yahoo Finance
Stoke Therapeutics, a Biotech Leader, Provides Several Opportunities as Revenue Soars by 117%
Dec 16 2025
Yahoo Finance
Stoke Therapeutics' CMO Offloads More Than 5,000 Shares: Is It Time for Shareholders to Sell?
Dec 11 2025
NASDAQ.COM
Post-Market Surge: Stoke Therapeutics, Alpha Tau Medical, and Compass Pathways Top Biotech Gainers
Dec 10 2025
NASDAQ.COM
STOK Surpasses Average Analyst Price Target
Dec 09 2025
NASDAQ.COM
Biogen and Stoke Present Zorevunersen Clinical Data, Significantly Improving Epilepsy Symptoms
Dec 05 2025
Globenewswire
Stoke and Biogen Present Zorevunersen Clinical Data, Significantly Improving Epilepsy Symptoms
Dec 05 2025
Newsfilter
Show More News
